Thompson Siegel & Walmsley’s Alexion Pharmaceuticals ALXN Stock Holding History

Thompson Siegel & Walmsley’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-42,986	Closed	-$7.9M	–	758
2021 Q2	$7.9M	Sell	42,986 -536,694	-93%	-$92.1M	0.11%	159
2021 Q1	$88.6M	Sell	579,680 -79,752	-12%	-$12.3M	1.26%	19
2020 Q4	$103M	Buy	659,432 +20,947	+3%	+$2.69M	1.65%	7
2020 Q3	$73.1M	Buy	638,485 +53,031	+9%	+$5.72M	1.42%	15
2020 Q2	$65.7M	Buy	585,454 +33,976	+6%	+$3.61M	1.32%	17
2020 Q1	$49.5M	Buy	+551,478	New	+$54.1M	1.18%	29

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Thompson Siegel & Walmsley's ALXN Position: Q3 2021 in Review

Thompson Siegel & Walmsley sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 42,986 shares — an estimated $7.9M sold.

Thompson Siegel & Walmsley first reported a position in ALXN in Q1 2020 and held it in 6 quarters. The position peaked at $103M in Q4 2020. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Thompson Siegel & Walmsley reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Thompson Siegel & Walmsley sold 42,986 Alexion Pharmaceuticals shares in Q3 2021, an estimated $7.9M.
Thompson Siegel & Walmsley first reported a position in Alexion Pharmaceuticals in Q1 2020 and held it in 6 quarters.
Thompson Siegel & Walmsley's Alexion Pharmaceuticals position peaked at $103M in Q4 2020.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Thompson Siegel & Walmsley's 13F filing for Q3 2021, filed 5 Nov 2021.